Oncolytics Biotech (TSE:ONC) Hits New 1-Year Low – Here’s Why

Oncolytics Biotech Inc. (TSE:ONC) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$0.86 and last traded at C$0.87, with a volume of 254159 shares traded. The stock had previously closed at C$0.93.

Analyst Ratings Changes

Separately, Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.

Oncolytics Biotech Stock Performance

The company has a market cap of C$69.37 million, a price-to-earnings ratio of -2.51 and a beta of 1.35. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The stock’s fifty day simple moving average is C$1.12 and its two-hundred day simple moving average is C$1.31.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.